No, TB Testing is Not Required for Plaquenil (Hydroxychloroquine) Monotherapy
Tuberculosis screening is not indicated when starting or taking Plaquenil (hydroxychloroquine) alone. TB testing is specifically required before initiating anti-TNF biologic therapy and other high-risk immunosuppressive medications, but hydroxychloroquine does not fall into this category.
Why TB Testing is Not Required for Plaquenil
Immunosuppression Profile
Hydroxychloroquine is classified as a disease-modifying antirheumatic drug (DMARD) with relatively mild immunomodulatory effects compared to biologics or high-dose immunosuppressants. The FDA drug label for Plaquenil does not include TB screening among its precautions or monitoring requirements 1.
Evidence-Based Guidelines
Current TB screening guidelines specifically target:
- Anti-TNF biologic therapy (infliximab, adalimumab, etanercept, etc.) - where TB screening with clinical risk assessment, chest x-ray, and interferon-gamma release assays (IGRAs) is mandatory 2
- Healthcare workers with occupational TB exposure risk 3
- High-risk immunosuppressed patients (HIV infection, organ transplant recipients, those on ≥15 mg prednisone daily for >1 month) 4, 5
Hydroxychloroquine is notably absent from these high-risk medication lists requiring TB screening.
When TB Screening IS Required
TB screening becomes necessary if you are taking or will be taking:
- Anti-TNF biologics (infliximab, adalimumab, etanercept, golimumab, certolizumab)
- Other biologics (rituximab, abatacept, tocilizumab)
- High-dose corticosteroids (≥15 mg prednisone daily for ≥1 month)
- Combination therapy with multiple immunosuppressants
The British Society of Gastroenterology specifically recommends TB screening (clinical risk stratification, chest x-ray, and IGRA) prior to commencing anti-TNF therapy 2, but this does not extend to hydroxychloroquine monotherapy.
Important Clinical Context
Risk with Combination Therapy
While hydroxychloroquine alone does not require TB screening, if you are taking it in combination with other immunosuppressive medications (methotrexate, leflunomide, biologics), TB screening may be indicated based on those other medications 6, 7.
Rare Case Reports
There is one case report of disseminated TB in a patient with Sjögren's syndrome on hydroxychloroquine monotherapy 8, but this represents an extremely rare occurrence and does not justify routine screening. The patient likely had other risk factors for TB reactivation.
When to Consider TB Testing Despite Plaquenil Use
You should discuss TB testing with your physician if you have:
- Recent close contact with someone with active TB
- History of inadequately treated TB
- Chest x-ray findings suggestive of old TB
- Immigration from or prolonged residence in high TB prevalence countries
- HIV infection
- Diabetes, chronic renal failure, or other conditions increasing TB risk
- Plans to start biologic therapy in the future
Monitoring That IS Required for Plaquenil
Instead of TB testing, Plaquenil requires:
- Baseline ophthalmologic examination within the first year, then annually after 5 years (or sooner if risk factors present) 1
- Periodic blood cell counts with prolonged therapy 1
- Monitoring for cardiac effects (ECG if indicated) 1
- Assessment for hypoglycemia risk 1
Bottom Line
Hydroxychloroquine monotherapy does not require TB testing before initiation or during treatment. This recommendation is consistent across international guidelines that specifically mandate TB screening only for anti-TNF biologics and high-risk immunosuppressive regimens. Focus your monitoring efforts on the actual risks associated with Plaquenil: retinal toxicity, cardiac effects, and hematologic abnormalities.